Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Gynecologic 1CNS 1

Conditions

Ovarian Neoplasms 1773Uterine Cervical Neoplasms 1499Endometrial Neoplasms 833Breast Neoplasms 434Carcinoma, Ovarian Epithelial 405Fallopian Tube Neoplasms 399Uterine Cervical Dysplasia 276Neoplasms 252Colorectal Neoplasms 179Uterine Neoplasms 173Peritoneal Neoplasms 170Vulvar Neoplasms 155Lung Neoplasms 150Pancreatic Neoplasms 141Prostatic Neoplasms 135Recurrence 128Stomach Neoplasms 126Colonic Neoplasms 116Papillomavirus Infections 115Melanoma 101Sarcoma 97Urinary Bladder Neoplasms 95Vaginal Neoplasms 93Carcinoma, Non-Small-Cell Lung 92Head and Neck Neoplasms 91Neoplasm Metastasis 83Esophageal Neoplasms 82Testicular Neoplasms 80Rectal Neoplasms 71Kidney Neoplasms 62

Interventions

STA 9090 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Disorders of Sex Development × Gynecologic × Clear all
NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Medical University Innsbruck

Phase 1/2 Terminated
133 enrolled 10 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon âš¡